X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6497) 6497
Book Chapter (96) 96
Magazine Article (8) 8
Book / eBook (2) 2
Newsletter (2) 2
Newspaper Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5522) 5522
life sciences & biomedicine (5070) 5070
humans (4910) 4910
animals (2636) 2636
female (2284) 2284
male (2235) 2235
recombinant fusion proteins - therapeutic use (1523) 1523
middle aged (1362) 1362
mice (1192) 1192
adult (1178) 1178
treatment outcome (1019) 1019
proteins (1001) 1001
aged (940) 940
recombinant fusion proteins - adverse effects (931) 931
immunology (879) 879
recombinant fusion proteins - administration & dosage (858) 858
recombinant fusion proteins - genetics (846) 846
oncology (690) 690
recombinant fusion proteins - metabolism (689) 689
research (681) 681
biotechnology & applied microbiology (616) 616
analysis (611) 611
antibodies, monoclonal - therapeutic use (599) 599
health aspects (590) 590
recombinant proteins (564) 564
care and treatment (554) 554
biochemistry & molecular biology (553) 553
hematology (540) 540
recombinant fusion proteins - immunology (537) 537
recombinant proteins - therapeutic use (520) 520
medicine, research & experimental (513) 513
research & experimental medicine (513) 513
gene expression (493) 493
abridged index medicus (481) 481
recombinant fusion proteins - pharmacology (478) 478
pharmacology & pharmacy (471) 471
research article (462) 462
cell biology (437) 437
cancer (433) 433
immunotherapy (416) 416
recombinant proteins - genetics (407) 407
science & technology - other topics (401) 401
surgery (400) 400
multidisciplinary sciences (383) 383
adolescent (381) 381
rats (380) 380
physiological aspects (377) 377
vaccines (377) 377
recombinant proteins - metabolism (375) 375
antigens (368) 368
antibodies (363) 363
medicine (362) 362
transplantation (360) 360
dose-response relationship, drug (355) 355
immunosuppressive agents - therapeutic use (349) 349
biotechnology (346) 346
clinical trials (345) 345
time factors (343) 343
amino acid sequence (342) 342
medicine & public health (341) 341
molecular sequence data (341) 341
retrospective studies (339) 339
aged, 80 and over (334) 334
microbiology (330) 330
drug therapy (325) 325
disease models, animal (317) 317
recombinant fusion proteins (317) 317
neurosciences & neurology (306) 306
recombinant proteins - adverse effects (305) 305
antibodies, monoclonal - adverse effects (301) 301
child (288) 288
mice, inbred balb c (288) 288
ophthalmology (286) 286
young adult (281) 281
cell line, tumor (278) 278
drug therapy, combination (276) 276
t cells (274) 274
science (273) 273
recombinant proteins - pharmacology (271) 271
cell line (269) 269
studies (269) 269
clinical trials as topic (266) 266
orthopedics (262) 262
mice, inbred c57bl (260) 260
recombinant fusion proteins - chemistry (260) 260
intravitreal injections (258) 258
genetic aspects (256) 256
double-blind method (255) 255
follow-up studies (255) 255
recombinant proteins - administration & dosage (255) 255
life sciences (252) 252
t-lymphocytes - immunology (252) 252
enzymes (248) 248
recombinant proteins - immunology (248) 248
vascular endothelial growth factor a - antagonists & inhibitors (246) 246
medical research (240) 240
vascular endothelial growth factor (239) 239
prospective studies (237) 237
drug administration schedule (234) 234
apoptosis (232) 232
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6548) 6548
Japanese (27) 27
Chinese (20) 20
French (20) 20
German (17) 17
Spanish (13) 13
Italian (7) 7
Danish (4) 4
Norwegian (2) 2
Russian (2) 2
Czech (1) 1
Dutch (1) 1
Finnish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Vaccine, ISSN 0264-410X, 01/2013, Volume 31, Issue 3, pp. 524 - 532
Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related... 
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2013, Volume 369, Issue 24, pp. 2313 - 2323
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 11/2014, Volume 12, Issue 11, pp. 1788 - 1800
...‐life could reduce infusion frequency. The A‐LONG study established the safety, efficacy and prolonged pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc... 
pharmacokinetics | factor VIII | hemophilia A | administration schedule | recombinant fusion proteins | drug | Drug | Administration schedule | Pharmacokinetics | Recombinant fusion proteins | Hemophilia A | Factor VIII | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Half-Life | Male | Hemorrhage - prevention & control | Immunoglobulin Fc Fragments - administration & dosage | Young Adult | Time Factors | Computer Simulation | Coagulants - administration & dosage | Adult | Factor VIII - adverse effects | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Immunoglobulin Fc Fragments - adverse effects | Immunoglobulin Fc Fragments - blood | Recombinant Fusion Proteins - administration & dosage | von Willebrand Factor - metabolism | Hemostasis - drug effects | Severity of Illness Index | Drug Administration Schedule | Treatment Outcome | Biomarkers - blood | Coagulants - blood | Hemophilia A - blood | Recombinant Fusion Proteins - blood | Models, Biological | Recombinant Fusion Proteins - pharmacokinetics | Adolescent | Factor VIII - administration & dosage | Hemorrhage - chemically induced | Infusions, Intravenous | Coagulants - adverse effects | Drug Monitoring | Hemophilia A - drug therapy | Proteins | Blood coagulation factor VIII | Analysis | Von Willebrand factor | Hemophilia | Index Medicus
Journal Article
Biotechnology and bioengineering, ISSN 0006-3592, 11/2014, Volume 111, Issue 11, pp. 2317 - 2325
Journal Article
Blood, ISSN 1528-0020, 03/2012, Volume 119, Issue 13, pp. 3031 - 3037
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
... — on which a BCR-ABL fusion gene codes for a protein with constitutive tyrosine kinase activity... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article